Lupin hits 32-month low; stock down 5% in two days

In past one-month, the stock declined 11.7% as compared to unchanged in Sensex.

Lupin receives US FDA for electrolyte replenisher

Premium

SI Reporter Mumbai

Last Updated : May 03 2017 | 1:16 PM IST

Shares of Lupin dipped 2.8% to Rs 1,267, extending its Tuesday’s 2.5% fall on the BSE, after the company on Friday after market hours said US health regulator issued three observations for its Goa plant. The stock is currently trading at its lowest level since August 26, 2014.

Recently, the company’s Goa manufacturing facility underwent an inspection by the US Food and Drug Administration (USFDA). The said inspection was completed on April 7, 2017, subsequently to which, the USFDA issued Form 483 citing three observations,” Lupin said in a BSE filing.

The company is in the midst of

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in